PDCD1 and non-small cell lung carcinoma: Given that tPD-L1 expression is the most well-established biomarker for PD-1 blockade cancer immunotherapy in patients with advanced NSCLC (Supplemental Figure 1, C and D) (39), we next investigated the relationship between tPD-L1 and the 3 soluble immune markers.